GeneNews is dedicated to providing innovative solutions for early cancer detection. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with actionable information to improve health outcomes through the early diagnosis of disease. We then work with large healthcare systems to develop and implement processes that lead to higher screening rates and improved metrics around performance and care.
In The News
GeneNews aims to fix compliance gap in early cancer screening
GeneNews (TSX:GEN) is addressing the major issue in early cancer screening - patient reluctance with inconvenient and intrusive screening methods - with a suite of differentiated molecular diagnostic tests that rely on a convenient in-office blood draw to find cancers of the colon, lung, breast and prostate, early. “If patients will not undergo screening because of the test, it severely limits the usefulness,” chairman and CEO, James Howard-Tripp, says in an interview with BioTuesdays.“And because there is this compliance gap, healthcare providers are actively seeking ways to improve cancer screening and improve patient outcomes.” For example, he points out that the American Cancer Society has set an “80-by-18” goal for healthcare providers to have 80% of their qualified patient population screened for colorectal cancer by 2018. “Today, less than 59% of patients have met this goal,” he says, adding that colorectal cancer is highly preventable when detected early.
Our Clinical Reference Lab
Our CLIA certified laboratory is dedicated to delivering innovative diagnostics and programs that improve cancer screening rates throughout the U.S.Innovative Diagnostic Laboratory (IDL) offers complete health risk assessment administration and chronic disease management programs consistent with nationally accepted protocols for Colorectal Cancer, Lung Cancer and Prostate Cancer.